{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053194","form_type":"8-K","ticker":null,"cik":"0001850838","company_name":"Omega Therapeutics, Inc.","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.824017+00:00","generated_at":"2026-06-02T22:25:00.853054+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Omega Therapeutics Q1 net loss $20.1M; cash $60M funds into Q1 2025; OTX-2002 advances","bullets":["Net loss of $20.1M for Q1 2024 vs $25.3M in Q1 2023; R&D expenses fell 23% to $15.4M.","Cash and cash equivalents $60.0M as of March 31, 2024; expected to fund operations into Q1 2025.","Phase 1/2 MYCHELANGELO I trial of OTX-2002 advanced to Cohort 5 at 0.3 mg/kg; additional data expected mid-2024.","Presented preclinical data for MYC-targeting epigenomic controller in EGFRi-resistant NSCLC at AACR 2024.","New preclinical data on durable gene upregulation to be presented at ASGCT 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053194","json":"https://secwatch.observer/filing/0000950170-24-053194.json","markdown":"https://secwatch.observer/filing/0000950170-24-053194.md","text":"https://secwatch.observer/filing/0000950170-24-053194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850838/000095017024053194/0000950170-24-053194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850838/000095017024053194/omga-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:25:00.853054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d5124cc5ece3cfc71816592827262f69fbf33ec","claim":"Omega Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $20.1 million.","evidence_excerpt":"Net loss for the first quarter of 2024 was $20.1 million, compared to $25.3 million for the first quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000095017024053194/0000950170-24-053194-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$20.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}